Haematologica, Vol 92, Issue 4, 566-567 doi:10.3324/haematol.10767
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Piccaluga, P. P.
Right arrow Articles by Pileri, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Piccaluga, P. P.
Right arrow Articles by Pileri, S. A.

Malignant Lymphomas

Expression of CD52 in peripheral T-cell lymphoma

Pier Paolo Piccaluga*, Claudio Agostinelli*, Simona Righi, Pier Luigi Zinzani, Stefano A. Pileri

Institute of Hematology and Medical Oncology "L. and A. Seràgnoli", S. Orsola-Malpighi Hospital, University of Bologna, 40138 Bologna, Italy

Correspondence: Stefano A. Pileri, MD, Chair of Pathology, Institute of Hematology and Medical Oncology "L. and A. Seràgnoli", Hematopathology Unit, St. Orsola-Malpighi Hospital, University of Bologna, via Massarenti 9, 40138 Bologna, Italy. Phone: international +39.051.6364034. Fax: international +39.051.6364037. E-mail: pileri{at}med.unibo.it

Peripheral T-cell lymphoma unspecified (PTCL/U) is a rare tumor characterized by poor treatment response and a dismal prognosis. We studied CD52 expression in 97 PTCL/U cases by immunohistochemistry on tissue-microarrays. Furthermore, CD52 gene expression was studied in 28 cases for which RNA was available. We found that CD52 is expressed in approximately 40% of PTCLs/U at the same level as in normal T-lymphocytes. Although other factors may play a role in the in vivo response to alemtuzumab, an anti-CD52 monoclonal antibody, the estimation of CD52 expression may provide a rationale for the selection of patients with a higher probability of treatment response.

Key words: T-cell lymphoma, CD52 expression.




This article has been cited by other articles:


Home page
 haematolHome page
A. Gazzola, C. Bertuzzi, C. Agostinelli, S. Righi, S. A. Pileri, and P. P. Piccaluga
Physiological PTEN expression in peripheral T-cell lymphoma not otherwise specified
Haematologica, July 1, 2009; 94(7): 1036 - 1037.
[Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
C Agostinelli, P P Piccaluga, P Went, M Rossi, A Gazzola, S Righi, T Sista, C Campidelli, P L Zinzani, B Falini, et al.
Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies
J. Clin. Pathol., November 1, 2008; 61(11): 1160 - 1167.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
S. M. Horwitz
Novel Therapies and Role of Transplant in the Treatment of Peripheral T-Cell Lymphomas
Hematology, January 1, 2008; 2008(1): 289 - 296.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Gallamini, F. Zaja, C. Patti, A. Billio, M. R. Specchia, A. Tucci, A. Levis, A. Manna, V. Secondo, L. Rigacci, et al.
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial
Blood, October 1, 2007; 110(7): 2316 - 2323.
[Abstract] [Full Text] [PDF]